Management of Chorea Following Post-Anoxic Brain Injury
For chorea developing after post-anoxic brain injury, initiate symptomatic treatment with dopamine-depleting agents (tetrabenazine or VMAT2 inhibitors) or dopamine receptor blockers (antipsychotics like risperidone or levomepromazine), while recognizing that this movement disorder often indicates basal ganglia injury and may be associated with better cognitive recovery than initially expected.
Understanding Post-Anoxic Chorea
Post-hypoxic movement disorders, including chorea, are uncommon but debilitating complications following cardiac arrest and anoxic brain injury. Chorea manifests as irregular, involuntary, jerky movements affecting any body part in random sequence 1. The neuroanatomical correlate is typically basal ganglia injury, demonstrated by T1 hyperintensities on MRI and hypometabolism on PET-CT in this region 1.
Diagnostic Workup
Before initiating treatment, obtain:
- Brain MRI with DWI sequences to assess for basal ganglia injury (T1 hyperintensities are characteristic) 1
- EEG monitoring to exclude underlying seizure activity, as post-anoxic patients commonly have epileptiform activity that may confound the clinical picture 2
- Exclude confounders: Ensure sedatives have been discontinued for at least 5 elimination half-lives (typically ≥24 hours for short-acting agents) 2
- Rule out metabolic derangements, residual medication effects, and other secondary causes
Pharmacological Treatment Algorithm
First-Line Options:
1. VMAT2 Inhibitors (Preferred)
- Tetrabenazine, deutetrabenazine, or valbenazine are considered first-line for chorea of any etiology 3
- These agents cause striatal dopamine depletion and are most effective for hyperkinetic movements
2. Dopamine Receptor Blockers
- Levomepromazine showed promising and often prompt responses in controlling post-hypoxic movement disorders, including hyperkinetic storms 1
- Risperidone has demonstrated significant reduction in bilateral chorea post-brain injury, decreasing overall care burden 4
- These antipsychotics are effective but monitor for cardiovascular effects in the post-arrest setting 2
Second-Line Options:
- Clonazepam: May suppress myoclonus but causes sedation 2
- Sodium valproate or levetiracetam: Known to suppress myoclonus of various origins 2
- Avoid phenytoin/fosphenytoin due to negative inotropic and vasodilating effects in post-cardiac arrest patients 2
Refractory Cases:
- Intrathecal baclofen showed first promising responses for severe post-hypoxic movement disorders 1
- Consider deep brain stimulation for disabling chorea despite optimal medical therapy 3
Important Clinical Considerations
Timing of Assessment: The 2025 ERC-ESICM guidelines emphasize that awakening from post-anoxic coma typically occurs within 3-4 days from ROSC, but sedatives must be stopped for sufficient time to enable reliable clinical examination 2. Movement disorders may emerge as sedation is weaned.
Prognostic Implications: Contrary to initial assumptions, patients with post-hypoxic movement disorders (including chorea) may demonstrate relatively good recovery of cognitive functions despite often severe physical deficits 1. The presence of chorea with basal ganglia dysfunction may indicate a more unfavorable physical outcome but is not necessarily devastating neurologically 1.
Remission Potential: Post-hypoxic movement disorders show a 58% remission rate, suggesting many patients will improve over time 1. This supports aggressive symptomatic management rather than early prognostic pessimism.
Avoid These Pitfalls
Do not confuse chorea with myoclonus: Post-anoxic myoclonus is more common (18-25% of comatose survivors) and has different treatment implications 5. Myoclonus best responds to combination therapy with clonazepam, levetiracetam, and primidone 1
Do not assume poor prognosis: While movement disorders indicate significant brain injury, they do not preclude meaningful recovery, particularly cognitive recovery 1
Avoid premature prognostication: The 2025 guidelines stress that prognostication should occur ≥72 hours post-ROSC after excluding all confounders 2. Movement disorders emerging during this period should not trigger premature withdrawal of life support
Monitor for sedation effects: High-dose antiepileptics and sedatives may delay awakening and prolong mechanical ventilation 2. Use the lowest effective doses
Treatment Response Monitoring
Assess treatment efficacy by:
- Reduction in involuntary movements interfering with care
- Ability to participate in rehabilitation
- Improvement in functional independence measures
- Serial neurological examinations for cognitive recovery
The holistic approach should focus on treating the patient rather than purely suppressing the movement disorder 2, balancing symptom control with minimizing medication side effects that could delay neurological recovery.